Please login to the form below
cancer drug funding
This page shows the latest cancer drug funding news and features for those working in and with pharma, biotech and healthcare.
NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo
Acknowledges unmet need. Patients with a form of skin cancer will be able to access Sanofi/Regeneron's new checkpoint inhibitor Libtayo via the NHS in England, after funding for the ... The cost-effectiveness watchdog has published guidance recommending
Latest news
-
Cancer charities criticise NICE's 'last-century methodology'
Group of 15 claims many new prostate cancer drugs will now ‘struggle to gain approval’. ... cancer drugs funding,” said the charity's chief executive Mark Flanagan.
-
England's Cancer Drugs Fund: Fixing a broken system
Meanwhile, shortly after the de-listing announcement, the Anglo-Swedish firm AstraZeneca said it would not even bother putting its newly approved ovarian cancer drug Lynparza (olaparib) up for funding via ... sustainable solution to cancer drug access
-
Decision to withdraw Jevtana in England ‘flawed’
Urologists and oncologists attack NHS England’s de-listing of Sanofi’s drug. A UK charity has denounced NHS England's decision to withdraw a new prostate cancer drug from its ... It is currently the only treatment for hormone resistant advanced
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Engaging the digital healthcare professional
When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... It was also shared by a student midwife who tweeted to
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
fox&cat
Fox&cat is a new kind of fully-integrated communications agency – one that delivers genuinely inspirational campaigns and programmes with equal...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
